全文获取类型
收费全文 | 687篇 |
免费 | 52篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 24篇 |
妇产科学 | 4篇 |
基础医学 | 48篇 |
口腔科学 | 5篇 |
临床医学 | 44篇 |
内科学 | 76篇 |
皮肤病学 | 14篇 |
神经病学 | 40篇 |
特种医学 | 66篇 |
外科学 | 93篇 |
综合类 | 8篇 |
预防医学 | 28篇 |
眼科学 | 236篇 |
药学 | 26篇 |
肿瘤学 | 23篇 |
出版年
2023年 | 4篇 |
2022年 | 5篇 |
2021年 | 19篇 |
2020年 | 3篇 |
2019年 | 14篇 |
2018年 | 21篇 |
2017年 | 15篇 |
2016年 | 15篇 |
2015年 | 6篇 |
2014年 | 18篇 |
2013年 | 42篇 |
2012年 | 30篇 |
2011年 | 36篇 |
2010年 | 27篇 |
2009年 | 22篇 |
2008年 | 37篇 |
2007年 | 30篇 |
2006年 | 34篇 |
2005年 | 30篇 |
2004年 | 24篇 |
2003年 | 35篇 |
2002年 | 33篇 |
2001年 | 23篇 |
2000年 | 30篇 |
1999年 | 29篇 |
1998年 | 14篇 |
1997年 | 13篇 |
1996年 | 3篇 |
1995年 | 7篇 |
1994年 | 3篇 |
1993年 | 11篇 |
1992年 | 15篇 |
1991年 | 8篇 |
1990年 | 14篇 |
1989年 | 10篇 |
1988年 | 9篇 |
1987年 | 8篇 |
1986年 | 4篇 |
1985年 | 3篇 |
1984年 | 2篇 |
1983年 | 3篇 |
1982年 | 4篇 |
1981年 | 2篇 |
1974年 | 2篇 |
1972年 | 2篇 |
1970年 | 3篇 |
1966年 | 3篇 |
1935年 | 1篇 |
1904年 | 1篇 |
1903年 | 2篇 |
排序方式: 共有740条查询结果,搜索用时 15 毫秒
11.
12.
Ultrasound, computed tomography and magnetic resonance imaging in patellar tendinitis 总被引:4,自引:0,他引:4
This prospective study describes the ultrasound, computerized tomography and magnetic resonance imaging findings in 16 cases of patellar tendinitis. In all cases tendon enlargement and reduced echogenicity were visible on ultrasound. Computerized tomography demonstrated enlargement of the tendon with reduced attenuation of the central portion. Magnetic resonance imaging showed focal tendon enlargement in all patients with high signal lesions in 88% of cases. This study has shown that patellar tendinitis may be identified with all three modalities. Ultrasound is recommended as the initial investigation in the assessment of patients with this condition. 相似文献
13.
Marie-Pierre Audrézet Christine Corbiere Said Lebbah Vincent Morinière Fran?oise Broux Ferielle Louillet Michel Fischbach Ariane Zaloszyc Sylvie Cloarec Elodie Merieau Véronique Baudouin Georges Deschênes Gwenaelle Roussey Sandrine Maestri Chiara Visconti Olivia Boyer Carine Abel Annie Lahoche Hanitra Randrianaivo Lucie Bessenay Djalila Mekahli Ines Ouertani Stéphane Decramer Amélie Ryckenwaert Emilie Cornec-Le Gall Rémi Salomon Claude Ferec Laurence Heidet 《Journal of the American Society of Nephrology : JASN》2016,27(3):722-729
Prenatal forms of autosomal dominant polycystic kidney disease (ADPKD) are rare but can be recurrent in some families, suggesting a common genetic modifying background. Few patients have been reported carrying, in addition to the familial mutation, variation(s) in polycystic kidney disease 1 (PKD1) or HNF1 homeobox B (HNF1B), inherited from the unaffected parent, or biallelic polycystic kidney and hepatic disease 1 (PKHD1) mutations. To assess the frequency of additional variations in PKD1, PKD2, HNF1B, and PKHD1 associated with the familial PKD mutation in early ADPKD, these four genes were screened in 42 patients with early ADPKD in 41 families. Two patients were associated with de novo PKD1 mutations. Forty patients occurred in 39 families with known ADPKD and were associated with PKD1 mutation in 36 families and with PKD2 mutation in two families (no mutation identified in one family). Additional PKD variation(s) (inherited from the unaffected parent when tested) were identified in 15 of 42 patients (37.2%), whereas these variations were observed in 25 of 174 (14.4%, P=0.001) patients with adult ADPKD. No HNF1B variations or PKHD1 biallelic mutations were identified. These results suggest that, at least in some patients, the severity of the cystic disease is inversely correlated with the level of polycystin 1 function. 相似文献
14.
Richebé P Rivalan B Baudouin L Sesay M Sztark F Cros AM Maurette P 《European journal of anaesthesiology》2005,22(11):858-863
BACKGROUND AND OBJECTIVE: The target effect-site concentration of propofol to insert a laryngeal mask airway was recently reported as almost 5 microg mL(-1). The present study aimed to determine the target effect-site concentration with target-controlled infusion of propofol to place classical larnygeal mask airway or current laryngeal tube in adult patients. METHODS: We included 40 patients scheduled for short gynaecological and radiological procedures under general anaesthesia in a randomized, double-blind manner using the Dixon's up-and-down statistical method. Monitoring included standard cardiorespiratory monitors, and bispectral index monitoring was used for all patients. Anaesthesia was conducted with a target-controlled infusion system: Diprifusor. The initial target plasma concentration of propofol was 5 microg mL(-1), and was changed stepwise by 0.5 microg mL(-1) increments according to Dixon's up-and-down method. Criteria for acceptable insertion were: Muzi's score < or = 2, and mean arterial blood pressure, heart rate or bispectral index variation <20% the baseline values. RESULTS: Target effect-site concentration of propofol required to insert laryngeal tube was 6.3 +/- 0.3 microg mL(-1) with Dixon method and ED50 was 6.1 microg mL(-1) (5.9-6.4) with logistic regression method. In the case of larnygeal mask airway they were 7.3 +/- 0.2 microg mL(-1) (Dixon method) and 7.3 microg mL(-1) (7.1-7.5; with logistic regression) respectively (P < 0.05). ED95 (logistic regression) was 6.8 microg mL(-1) (5.9-7.6) for laryngeal tube and 7.7 microg mL(-1) (7.3-8.0) for larnygeal mask airway (P < 0.05). Haemodynamic incidents were 55% in the larnygeal mask airway group vs. 30% in the laryngeal tube group (P < 0.05). CONCLUSIONS: The target effect-site concentration of propofol for insertion of laryngeal tube was lower than for larnygeal mask airway (P < 0.05), with a consequent reduction of the propofol induced haemodynamic side-effects. 相似文献
15.
Marc Labetoulle Andrea Leonardi Mourad Amrane Dahlia Ismail Jean-Sébastien Garrigue Gerhard Garhöfer Maite Sainz de la Maza Christophe Baudouin 《Clinical therapeutics》2018,40(11):1894-1906
Purpose
Results from a 6-month double-masked and a 6-month open-label study (SANSIKA) established the efficacy and safety of once-daily 0.1% cyclosporin A cationic emulsion (CsA CE) in severe keratitis due to dry eye disease (DED). This article presents results from the Post-SANSIKA study, a 24-month extension of SANSIKA assessing the sustained efficacy of CsA CE after treatment discontinuation.Methods
Time to relapse (corneal fluorescein staining [CFS] score ≥4 [modified Oxford scale]) was assessed after treatment discontinuation in patients from the SANSIKA study who had CFS improvement from a score of 4 to ≤2 after 6 or 12 months of treatment with CsA CE.Findings
Of 62 patients who achieved a CFS score ≤2 at the end of the SANSIKA study, 38 did not relapse and 24 (39%) relapsed during the 24-month period after CsA CE discontinuation; the latter (relapse) group comprised 35% of patients initially treated with CsA CE for 12 months in SANSIKA versus 47% of those treated for 6 months only. Patients spent the most time during the extension study at CFS scores of 1 or 2 (median duration of 8.5 weeks and 14.7 weeks per year, respectively), indicating marked improvement, and less time at scores of 3, 4, or 5 (median time, 2.0 weeks, 0 weeks, and 0 weeks per year). Of 23 patients eligible for safety analysis (ie, patients who received the study treatment at least once), 12 (52.2%) reported a total of 26 ocular adverse events (AEs). Among these, 5 ocular AEs, reported in 5 patients (21.7%), were considered related to study treatment: 3 events of mild instillation site pain in 3 patients (13.0%) and eye discharge and foreign body sensation, each reported in 1 patient (4.3%). Only 1 systemic AE (nasal congestion), reported in 1 patient (4.3%), was considered related to study treatment. None of the AEs led to treatment discontinuation.Implications
The majority of patients who discontinued CsA CE after experiencing DED improvement in the SANSIKA study did not experience a relapse in this 24-month follow-up study; these patients spent the most time at CFS scores consistent with marked improvement. CsA CE had a favorable safety/tolerability profile over 2 years. Treatment for up to 12 months with CsA CE provides sustained improvements in patients with severe keratitis due to DED. EudraCT registration no. 2012-002066-12. 相似文献16.
17.
18.
19.
20.
Camille Nicolas Vincent Vuiblet Veronique Baudouin Marie-Alice Macher Isabele Vrillon Nathalie Biebuyck-Gouge Maud Dehennault Sophie Gié Denis Morin Hubert Nivet François Nobili Tim Ulinski Bruno Ranchin Maria Chiarra Marinozzi Stéphanie Ngo Véronique Frémeaux-Bacchi Christine Pietrement 《Pediatric nephrology (Berlin, Germany)》2014,29(1):85-94